Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
Two-Drug Regimen Offers Better Health-Related Quality of Life in Advanced Renal Cell Carcinoma
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
Telaglenastat Fails to Improve Outcomes in Previously Treated Metastatic RCC
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
Combo Continues to Show Superior Efficacy vs Sunitinib in Advanced Clear Cell Renal Cell Carcinoma
Pembrolizumab plus axitinib improved progression-free and overall survival.
Pembrolizumab After RCC Surgery: Potential New Standard of Care
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Understanding Adverse Effects Associated With Immune-Based Combination Therapies for Metastatic Renal Cell Carcinoma
A meta-analysis of phase 3 randomized control trials sought to identify the TRAEs associated with 7 therapeutic regimens for the treatment of mRCC.
Obesity Paradox in Renal Cell Carcinoma: Why Do Patients Who Are Obese Have Improved Survival?
A review of retrospective data sought to better understand the relationship between obesity and survival in renal cell carcinoma.
Active Surveillance Deemed “Justifiable” Option for Metastatic Renal Cell Carcinoma
For real-world patients with mRCC, active surveillance may be a worthwhile alternative to immediate systemic therapy.
Local Salvage Therapy Effective for Local, Regional Recurrence of RCC
Local surgery or ablation may be most appropriate for patients with a solitary site of locoregional recurrence following definitive surgery for clinically localized renal cell carcinoma, according to investigators.
Pembrolizumab Plus Lenvatinib Prolongs Survival in Renal Cell Carcinoma
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.
Factors Associated With Response to Nivolumab in Renal Cell Carcinoma
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
Fotivda Approved for Relapsed/Refractory Advanced Renal Cell Carcinoma
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Palliative Care Use in Advanced Renal Cell Carcinoma Linked to Socioeconomic Groups
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Race Reporting in GU Cancers Indicates Relative Overrepresentation of White Individuals
Lythgoe et al studied patterns of race reporting in genitourinary (GU) cancer trials.
Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...